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ABSTRACT
Objective: The objective of the study was to investigate the memory-enhancing activity for erythrinine (ring-c-oxygenated Erythrina alkaloid) from 
leaf extract of Erythrina indica in mice.
Methods: The study protocol designed in the way that it was carried out for 21 successive days by administrating the 5 mg/kg, s.c doses of isolated 
erythrinine to mice and the profile was challenged against the mice feeds with normal saline as a positive control and the mice treated with 5 mg/kg, 
s.c corticosterone as a negative control for the amnesia using Morris water maze test method.
Results: Erythrinine-administered mice are showing remarkable retention of the memory (9.07±0.52) on the 21st day as such of the positive control 
normal saline (10.14±0.22) and against the negative control corticosterone-injected mice (70.86±0.54).
Conclusions: The dose of 5 mg/kg s.c of isolated erythrinine from the leaf of E. indica shows the remarkable memory enhancement when it was 
investigated with the memory weakening induced test by corticosterone in mice’s using 5 mg/kg s.c. However, further studies required to elucidate 
the exact mechanism of action for developing its as potent memory-enhancing drug.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurological brain disorder. AD is also known 
as dementia, a group of disorders that impair mental functioning. Memory 
loss is one of the earliest symptoms, along with a gradual decline of proper 
thinking abilities called cognitive function and change in personality [1-3].
On early stage of the person with Alzheimer disease, may have the 
symptoms like difficulty in remembering the daily planned activities 
and misperception (short term memory loss). On long term, the disease 
slowly goes worst such as start forgetting the words, language, loss 
of motivation, and faced behavioral issue in the society which may 
gradually isolated from the family and society and as a worst cause 
ultimately leading to death [4,5].
The exact causes of the AD were still under investigation, and most of the 
history of investigation is outcome reason as genetic or any inadvertent 
injuries and over the period of hypertension or depression [6].
Yoga, physical exercise, and creating the stress-free environment 
such as listening music, reading books, and maintain the stabilized 
blood pressure may help to decrease the threat of AD still there are no 
medications or supplements that used to decrease risk immediately [7].
Treating the people with antipsychotics drugs is recommended for the 
behavioral problems and psychosis due to dementia, but not usually 
recommended due to its adverse risks [8,9].
In early studies, different parts of Erythrina and Erythrina alkaloids are used 
as a traditional medicine in various diseases such as anti-inflammatory, 
antioxidant, sedative, antiasthmatic, and antiepileptic [10,11].
Even in our previous research, we proved the antihyperlipidemic, 
convulsion, and stress-induced alteration on lipid profile in rats using 
the leaf extract of Erythrina indica [12].
From the source of literature, we found the extract of Erythrina 
variegate already proved for the memory-enhancing activity and 
manages the dementia [13].
In continuation of our research, we attempt early erythrinine for its 
Insilco evaluation and QSAR studies. To explore further medicinal 
uses of the isolated erythrinine from the leaf extract of the E. indica, 
an attempt was made to carry out the memory-enhancing effect to 




The fresh leaf of E. indica was collected from the mature plant in 
and around the city of Chennai, Tamil Nadu, India, and dried under 
shade. The plant was authenticated by Dr. Sasikala, Department of 
Pharmacognosy, Captain Srinivasamoorty Drug Research Institute of 
Ayurveda, Chennai [12].
Isolation of erythrinine
The powdered, air-dried leaf of E. indica was first extracted with hexane 
and then with methanol, and the alkaloids subsequently isolated by 
treating the crude leaf extracts of E. indica with 1% hydrochloric acid, 
followed by basification and extraction with chloroform. The alkaloidal 
fraction obtained from the methanol extract was fractionated by column 
chromatography on Sephadex LH 20 to yield a crystalline substance 
erythrinine with 85–90% purity (Fig. 1) [14-16].
Animal’s used
Male albino mice (25–40 g) were used for the proposed study. All the 
mice are well maintained in a ventilated room with suitable alternate 
source for light/dark cycle in polypropylene cages. The mice were free 
access to food and water. The standard pellet feed from Hindustan Lever 
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Limited, Bangalore, was used to feed for the mice to acclimatize for at 
least week before experimentation. Ethical committee clearance was 
obtained from the Institutional Animal Ethics Committee of CPCSEA 
and all cares were followed as per regulation.
Study plan
Experiments were designed as three groups, each group of six male 
albino mice with that the weight range of 25–40 g. The test drug, isolated 
erythrinine 5 mg/kg s.c doses were administered for 21 days in sequence 
as per study plan, 30 min before administration of corticosterone 
injection which is used as negative control. Corticosterone (5 mg/kg) 
was dissolved in absolute ethanol and subsequently diluted in water to 
the final concentration of 10% ethanol and injected subcutaneously in 
a volume of 1 ml/kg [17,18].
•	 Group-I:	Positive	control	(Normal	saline	2	ml/kg,	p.o	[0.9%	w/v]).
•	 Group-II:	Negative	control	(Corticosterone	inj.,	5	mg/kg	s.c).
•	 Group-III:	5	mg/kg	s.c	doses	of	 isolated	erythrinine	 for	21	days,	
30 min before corticosterone administration (5 mg/kg s.c).
Morris water maze test
Setting up the water maze
Water maze is set up as a round pool, about 6 feet in diameter and about 
3 feet deep. Filled the water maze with tap water, which should be close 
to 26°C. Placed the escape platform in the center of the pool. During 
training, it must be exposed, 1 inch above the water. This teaches the 
mice are that there is a platform and that it is the way to get out of the 
water [13].
Then, escape platform was hidden and will not be visible color change 
due to milk. Pre-training for animals was given as per standard 
procedure [18].
Water maze testing
During execution of the experiments, the pool was added with milk for 
color difference with water and to differ from the training. The circular 
pool was filled up to 30 cm in height and maintained the temperature 
of 18°C. A white platform (6 cm in diameter and 29 cm in height) was 
centered in one of four quadrants of the pool (Southeast area) and 
submerged 1 cm below the water surface so that it was invisible at water 
level. In the water maze experiments, the 1st week of the experiment was 
dedicated to swimming training for 60 s for all group mice. Remaining 
3 weeks of treatment were investigated with all the groups. In these days, 
the mice were given one session of two trails each day for 21 days. During 
each trial, the mouse’s escape latency, measured with a stopwatch, was 
recorded. In each group, six mice were allowed for investigation and the 
parameter was averaged for each session of trials and for each mouse. 
If any one of the mice is located the correct platform earlier to 120s, 
will allow to remain the platform for 10s and note the readings. If the 
mice not identified the correct platform within 120 s, it was reseated 
for 10 s on the platform for a break. The platforms are rearranged and 
bring back to testing condition and fixed position for next trail. The same 
testing was studied for more than each day up to 21 days study periods 
and all the parameters are noted. As a climax of the study protocol, on 
the 21 days, mice were given a probe trial which considered of removing 
the platform from the pool and allowing the mice to swim for 60 s in 
search of it and the outcome of the results and recorded. All the records 
calculated the swimming time of the mice in the pool quadrant, where 
the platform had previously been placed. Isolated erythrinine was 
administered subcutaneously 10 min before the consecutive training.
Statistical analysis
The statistical significance of the results of Morris water maze was 
analyzed using ANOVA, followed by Dunnett’s test, p<0.05 was 
considered as statistical significance.
RESULTS
The study protocol designed in the way it was carried out for 21 
successive days by administrating the 5 mg/kg, s.c doses of isolated 
erythrinine to mice and the profile was challenged against the mice 
feeds with normal saline as a positive control and the mice treated with 
5 mg/kg, s.c corticosterone as a negative control for the amnesia using 
Morris water maze teat method. Erythrinine-administered mice are 
showing sowing remarkable retention of the memory (9.07±0.52) on the 
21st day as such of the positive control normal saline (10.14±0.22) and 
against the negative control corticosterone-injected mice (70.86±0.54).
Positive control mice administered only with the normal saline 
(Group	 I),	 identified	 the	 same	 submerged	 platform	 as	 same	 as	 from	
the 1st day (13.14±0.25) and 21st day (10.14±0.22) with minimal 
change with remarkable transfer latency. When administering only 
corticosterone injection (5 mg/kg) group which act as a negative control, 
will show the memory impairment rapidly from the 0th day (9.76±0.32) 
to 21st (70.86±0.54) which will be higher rate when compare with 
the only saline treated mice’s. Isolated erythrinine treated mice 
(5 mg/kg) shown good response in identifying the platform compare to 
Corticosterone injected mice’s and also pointedly than the saline treated 
mice’s from 9th (15.97±0.27) day to 21st (9.07±0.52) day which means 
the mice’s start to response to the Isolated Erythrinine from the 9th day 
and when 21st day it shows the its show the equal response as such of 
saline only treated group (10.14±0.22), Where has when it compared 
with the corticosterone only injected group shows impairment approx. 
7 times (70.86±0.54) (Table 1). The above results confirm that the 
isolated erythrinine-injected mice (9.07±0.52) are having learning and 
memory-enhancing properties.
DISCUSSION AND CONCLUSIONS
The isolated erythrinine from the leaf of E. indica shows the remarkable 
memory enhancement when it was investigated with the memory Fig. 1: Structure of erythrinine
Table 1: Effect of isolated erythrinine transfer latencies of mice on Morris water maze test
Group Treatment Transfer latency (s)
0 3 6 9 12 15 18 21
I Normal saline 2 mL/kg, p.o 13.14±0.25 15.14±0.87 13.98±0.52* 12.14±0.59* 11.14±0.82* 11.64±0.52* 13.74±0.52* 10.14±0.22*
II Corticosterone 5 mg/kg, s.c 9.76±0.32 14.00±0.52 25.04±0.22 36.04±0.52 49.25±0.47 56.87±0.52 67.34±0.92 70.86±0.54
III Corticosterone+isolated 
erythrinine 5 mg/kg s.c
7.87±0.52 9.14±0.72 12.84±0.52 15.97±0.27 12.74±0.52* 11.76±0.98* 11.34±0.82* 9.07±0.52*
Values are expressed as mean±SEM, ANOVA followed by Dunnett’s test, six male albino mice in each group. *p<0.001, as compared to corticosterone-injected group
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weakening induced test by corticosterone in mice using 5 mg/kg s.c. 
The dose of 5 mg/kg s.c of isolated erythrinine was challenged with 
the only saline group mice as positive control and corticosterone only 
administered mice as a negative control and established results proved 
that the dose of 5 mg/kg s.c having the memory-enhancing property 
and used in the treatment of dementia.
The probable mechanism of action, form literature is discussed in 
brief below. Corticosterone significantly impaired other forms of 
hippocampus-dependent memory such as object recognition and 
retrieval of the passive avoidance behavior. Corticosterone, the 
predominant glucocorticoid in rodents, chronic administration 
of corticosterone it damages hippocampal subregion CA3 that 
leads to impair spatial memory. Also chronically elevated levels of 
corticosterone injection administration is mice for 21 days can produce 
neuronal atrophy and cell death in the hippocampus while leaving other 
brain regions, the elevated levels of corticosterone changes in various 
neurotransmitters such as catecholamine’s, serotonin and aminobutyric 
acid	 (GABA)	 in	 several	 brain	 structures.	 In	 the	 hippocampus,	
corticosterone	 impairs	 GABA-mediated	 inhibitory	 neurotransmission	
and causes neurodegeneration through diminished expression of 
GABAA	 receptors.	 High	 amounts	 of	 corticosterone	 enhance	 action	 of	
norepinephrine through adrenal receptors and increased dopamine 
turnover in prefrontal cortex is accompanied by the decreased spatial 
memory performance [3,15].
Erythrinine is a ring-c-oxygenated Erythrina alkaloid which acts as 
inhibition of ache and increases the acetylcholine level in the brain 
through	 the	 involvement	 of	 GABA-benzodiazepine	 pathway	 virtue	
of which susceptible brain cells get exposed to less oxidative stress 
resulting in reduced brain damage and improved neuronal function, 
thereby enhancing the memory activity. However, further studies 
required to elucidate the exact mechanism of action for developing its 
as potent memory-enha ncing drug [3].
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